Author: Ji, Yuan; Yuan, Shijie
Title: Lessons Learned from the Bayesian Design and Analysis for the BNT162b2 COVID-19 Vaccine Phase 3 Trial Cord-id: z4vqbd7j Document date: 2021_1_8
ID: z4vqbd7j
Snippet: The phase III BNT162b2 mRNA COVID-19 vaccine trial is based on a Bayesian design and analysis, and the main evidence of vaccine efficacy is presented in Bayesian statistics. Confusion and mistakes are produced in the presentation of the Bayesian results. Some key statistics, such as Bayesian credible intervals, are mislabeled and stated as confidence intervals. Posterior probabilities of the vaccine efficacy are not reported as the main results. We illustrate the main differences in the reportin
Document: The phase III BNT162b2 mRNA COVID-19 vaccine trial is based on a Bayesian design and analysis, and the main evidence of vaccine efficacy is presented in Bayesian statistics. Confusion and mistakes are produced in the presentation of the Bayesian results. Some key statistics, such as Bayesian credible intervals, are mislabeled and stated as confidence intervals. Posterior probabilities of the vaccine efficacy are not reported as the main results. We illustrate the main differences in the reporting of Bayesian analysis results for a clinical trial and provide four recommendations. We argue that statistical evidence from a Bayesian trial, when presented properly, is easier to interpret and directly addresses the main clinical questions, thereby better supporting regulatory decision making. We also recommend using abbreviation"BI"to represent Bayesian credible intervals as a differentiation to"CI"which stands for confidence interval.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date